Technology Profits Confidential

The world of tech and biotechnology will provide endless opportunity for growth and wealth for investors who know where to look.

Technology Profits Confidential is your one-stop shop for the companies of tomorrow's technology... and how you can profit from them.

Update From Recent Trip, and a Sell Recommendation

I spent most of Tuesday on a road trip to Miami with Patrick. While there, we visited Frank Jaksch, CEO of ChromaDex Corp., at the former IVAX Corp. building. If you recall, IVAX is now part of Teva Pharmaceuticals, and Dr. Phillip Frost, Teva's chairman, keeps his offices there. ChromaDex specializes in phytochemicals, or plant-based compounds. It provides laboratory-grade phytochemicals to academic researchers, and it also sells its own retail dietary supplements.

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.


Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco